ImmuCell Corporation (ICCC) - יתרת חוב לטווח ארוך להון עצמי

The long-term debt-to-equity trend demonstrates the financial stability of ImmuCell Corporation, where 0.33 represents the latest metric reading. ImmuCell Corporation relies on US plants for the production of diagnostic systems and veterinary products. The business is protected by patents for First Defense drugs and strict USDA oversight. Modernization includes the implementation of AI manipulators to automate sterile filling and pasteurization.

Investors utilize multiples to verify the financial stability of an issuer. This long-term debt financial leverage ratio reflects the proportion of loans with maturities exceeding one year relative to equity. The current value of 0.33 demonstrates the degree of the company's dependence on external financing. For ImmuCell Corporation (ICCC) in its maturity stage, such a capital structure is critical when scaling the production of First Defense. Low leverage confirms the business's ability to expand its geographic footprint without critical debt risks.